Divi's Laboratories share price, financials and monitoring
Divi's Laboratories manufactures pharmaceutical ingredients and provides custom synthesis. Customer programmes, product mix, utilisation and capital expenditure influence its results.
Dates and sources
The last NSE bhavcopy close is dated 4 Nov 2026. Valuation observations are dated 4 Nov 2026. The latest financial quarter ends 30 Jun 2026. These are separate observation dates, not live quotes. Financial reporting basis: consolidated.
Read the Nifty drivers report · Understand index funds and ETFs · NSE daily reports
Year ended 2026-03-31 and the latest quarter
The tables use one reporting basis across the displayed history, preferring consolidated where sufficient history is available. Each row identifies its period and original filing. Profit is attributable to owners where disclosed; otherwise total profit is labelled.
Revenue history
A rising top line is evidence of scale, not proof of value creation. Read it with profit, capital efficiency, cash conversion and the business-specific guideposts above.
₹ crore values are presented as filed or normalized from company/exchange financial results. Banks and NBFCs use total income because interest is part of their operating business. Industrial companies use revenue where available.
Historical values can be restated. EPS retains the share basis in its original filing and may not be directly comparable across corporate actions. Gaps in annual periods remain gaps; the source and reporting basis are retained.
| Year ended | Revenue | PAT | Reported EPS | Basis | Evidence |
|---|---|---|---|---|---|
| Year ended 2022-03-3131 Mar 2022 | ₹8,960 cr | ₹2,960 cr | 111.52 | Consolidated · PAT: owners | Filing ↗ |
| Year ended 2023-03-3131 Mar 2023 | ₹7,768 cr | ₹1,823 cr | 68.69 | Consolidated · PAT: owners | Filing ↗ |
| Year ended 2024-03-3131 Mar 2024 | ₹7,845 cr | ₹1,600 cr | 60.27 | Consolidated · PAT: owners | Filing ↗ |
| Year ended 2025-03-3131 Mar 2025 | ₹9,360 cr | ₹2,191 cr | 82.53 | Consolidated · PAT: owners | Filing ↗ |
| Year ended 2026-03-3131 Mar 2026 | ₹10,560 cr | ₹2,568 cr | 96.75 | Consolidated · PAT: owners | Filing ↗ |
Eight reported quarters
Publication date is shown separately from the period end. A June quarter was not knowable on 30 June; it entered the public record only when the company filed it.
| Quarter ended | Revenue | PAT | Reported EPS | Published | Evidence |
|---|---|---|---|---|---|
| 30 Jun 2026Consolidated · PAT: owners | ₹3,080 cr | ₹902 cr | 33.95 | 1 Aug 2026 | Filing ↗ |
| 31 Mar 2026Consolidated · PAT: owners | ₹2,831 cr | ₹751 cr | 28.31 | 23 May 2026 | Filing ↗ |
| 31 Dec 2025Consolidated · PAT: owners | ₹2,604 cr | ₹583 cr | 21.98 | 11 Feb 2026 | Filing ↗ |
| 30 Sept 2025Consolidated · PAT: owners | ₹2,715 cr | ₹689 cr | 25.97 | 7 Nov 2025 | Filing ↗ |
| 30 Jun 2025Consolidated · PAT: owners | ₹2,410 cr | ₹545 cr | 20.49 | 6 Aug 2025 | Filing ↗ |
| 31 Mar 2025Consolidated · PAT: owners | ₹2,585 cr | ₹662 cr | 24.93 | 17 May 2025 | Filing ↗ |
| 31 Dec 2024Consolidated · PAT: owners | ₹2,319 cr | ₹589 cr | 22.2 | 3 Feb 2025 | Filing ↗ |
| 30 Sept 2024Consolidated · PAT: owners | ₹2,338 cr | ₹510 cr | 19.2 | 9 Nov 2024 | Filing ↗ |
Use the metric that fits the business.
ROCE is not shown for banks and NBFCs because deposits and borrowings are operating raw material rather than ordinary financing. Missing or inapplicable values remain unavailable.
Who owns the company?
Shareholding is shown from the latest available filing. Institutional subtotals depend on the filing taxonomy and are labelled by their source basis.
Profit is only one part of the evidence.
These are investigation prompts, not pass-or-fail verdicts. Business model, working-capital structure and reporting basis determine how each value should be interpreted.
Dated evidence, linked to its source.
The page shows selected annual and quarterly periods. The financial tables, market observations and ownership figures can have different dates.
Related company and methodology pages
Divi's Laboratories FAQ
What does Divi's Laboratories do?
Divi's Laboratories manufactures pharmaceutical ingredients and provides custom synthesis. Customer programmes, product mix, utilisation and capital expenditure influence its results.
What should investors monitor for Divi's Laboratories?
Important operating evidence includes custom synthesis mix, capacity utilisation, research programmes, capital expenditure. These are research guideposts, not automatic trading signals.
Are the Divi's Laboratories financials consolidated or standalone?
Altys prefers consolidated financials when available and labels the reporting basis in each table. The latest annual row on this page is consolidated.
Does Altys recommend buying or selling Divi's Laboratories?
No. Altys provides sourced financial data, research context and monitoring infrastructure. It does not issue a buy, sell or hold recommendation on this page.
Research Divi's Laboratories once. Keep watching what changes.
Altys can connect new results, filings, concalls, guidance, ownership and company-specific KPIs with the investment team’s original thesis and portfolio context.